Evidence map›Paper›PMID 28507569›Full record

ArticleArchives of medical science : AMS2017

Effects of a novel ascorbate-based protocol on infarct size and ventricle function in acute myocardial infarction patients undergoing percutaneous coronary angioplasty.

Cristóbal Ramos, Roberto Brito, Jaime González-Montero, Nicolás Valls, Juan G Gormaz, Juan C Prieto, Rubén Aguayo, Ángel Puentes, Viviana Noriega, Gonzalo Pereira and 2 more

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Vitamin C in the critically ill - indications and controversies.World journal of critical care medicine · 2018
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Cristóbal RamosFaculty of Medicine, University of Chile, Santiago, Chile.
Roberto BritoMolecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Jaime González-MonteroFaculty of Medicine, University of Chile, Santiago, Chile.
Nicolás VallsFaculty of Medicine, University of Chile, Santiago, Chile.
Juan G GormazMolecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Juan C PrietoFaculty of Medicine, University of Chile, Santiago, Chile.
Rubén AguayoSan Juan de Dios Hospital, Santiago, Chile.
Ángel PuentesSan Juan de Dios Hospital, Santiago, Chile.
Viviana NoriegaFaculty of Medicine, University of Chile, Santiago, Chile.
Gonzalo PereiraFaculty of Medicine, University of Chile, Santiago, Chile.
Tamara PalavecinoFaculty of Medicine, University of Chile, Santiago, Chile.
Ramón RodrigoMolecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
University of Chile · CLHospital San Juan de Dios · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study was designed to test the hypothesis that high-dose ascorbate prior to reperfusion followed by low chronic oral doses ameliorate myocardial reperfusion injury (MRI) in acute myocardial infarction patients subjected to primary percutaneous coronary angioplasty (PCA). MATERIAL AND

methodsA randomized double-blind placebo-controlled and multicenter clinical trial was performed on acute myocardial infarction (AMI) patients who underwent PCA. Sodium ascorbate (320 mmol/l,

resultsThe ascorbate group showed significantly higher ascorbate and FRAP levels and a decrease in the GSH levels at M2 and M3 (

conclusionsAscorbate given prior to reperfusion did not show a significant difference in infarct size or ejection fraction. However, it improved the change in ejection fraction determined between 7-15 days and 2-3 months. This result hints at a possible functional effect of ascorbate to ameliorate MRI.

Indexed as

ascorbatemyocardial reperfusion injuryoxidative stress

Identifiers

PMID28507569
PMCPMC5420620
OpenAlexW2405439801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.